Microphthalmia-anophthalmia-coloboma
ORPHA:98555CategoryAutosomal dominant, Autosomal recessive, X-linked recessiveAntenatal, Neonatal
Эпидемиология40
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Prevalence at birth | 1-9 / 100 000 | 8.3 | Europe | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Europe | Class only |
| Prevalence at birth | 1-9 / 100 000 | 2.9 | Belgium | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Belgium | Class only |
| Prevalence at birth | 1-9 / 100 000 | 9.8 | Austria | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Austria | Class only |
| Prevalence at birth | 1-5 / 10 000 | 36.4 | Denmark | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Denmark | Class only |
| Prevalence at birth | 1-9 / 100 000 | 7.3 | France | Value and class |
| Point prevalence | 1-9 / 100 000 | — | France | Class only |
| Prevalence at birth | 1-9 / 100 000 | 5.8 | Germany | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Germany | Class only |
| Prevalence at birth | 1-5 / 10 000 | 17.7 | Hungary | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Hungary | Class only |
| Prevalence at birth | 1-9 / 100 000 | 3.6 | Ireland | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Ireland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11 | Italy | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Italy | Class only |
| Prevalence at birth | 1-5 / 10 000 | 25.9 | Malta | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Malta | Class only |
| Prevalence at birth | 1-5 / 10 000 | 11.1 | Netherlands | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Netherlands | Class only |
| Prevalence at birth | 1-9 / 100 000 | 6.4 | Norway | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Norway | Class only |
| Prevalence at birth | 1-9 / 100 000 | 2.4 | Poland | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Poland | Class only |
| Prevalence at birth | 1-5 / 10 000 | 13.1 | Croatia | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Croatia | Class only |
| Prevalence at birth | 1-5 / 10 000 | 14.4 | Spain | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Spain | Class only |
| Prevalence at birth | 1-5 / 10 000 | 12.3 | Switzerland | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Switzerland | Class only |
| Prevalence at birth | 1-9 / 100 000 | 3.9 | United Kingdom | Value and class |
| Point prevalence | 1-9 / 100 000 | — | United Kingdom | Class only |
| Prevalence at birth | 1-5 / 10 000 | 12.9 | Ukraine | Value and class |
| Point prevalence | 1-5 / 10 000 | — | Ukraine | Class only |
| Prevalence at birth | 1-9 / 100 000 | 5.2 | Portugal | Value and class |
| Point prevalence | 1-9 / 100 000 | — | Portugal | Class only |
| Prevalence at birth | 1-5 / 10 000 | 18 | United States | Value and class |
| Point prevalence | 1-5 / 10 000 | — | United States | Class only |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)